Krick Anthony J 4
4 · OptiNose, Inc. · Filed Mar 10, 2023
Insider Transaction Report
Form 4
OptiNose, Inc.OPTN
Krick Anthony J
Chief Accounting Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-03-08+50,750→ 50,750 totalExercise: $1.90Exp: 2033-03-08→ Common Stock (50,750 underlying) - Award
Common Stock
2023-03-08+33,833→ 33,833 total
Footnotes (2)
- [F1]Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 8, 2024, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer provided that, in the event XHANCE is approved by the U.S. FDA for commercialization for the treatment of chronic rhinosinusitis or substantially similar indication, then any unvested RSUs shall become fully-vested on the four month anniversary of such approval, subject to the Executive's continued service through such date. Each RSU represents the right to receive one share of common stock of OptiNose, Inc.
- [F2]The option vests and becomes exercisable over a four-year period commencing on March 8, 2023. Twenty-five percent (25%) of the option vests and becomes exercisable on March 8, 2024, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.